Cargando…
NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study
BACKGROUND: The risk of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) can be easily evaluated by noninvasive scoring systems, of which the NAFLD fibrosis score (NFS) is the most commonly used. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a new predictor of cardiovascular even...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742334/ https://www.ncbi.nlm.nih.gov/pubmed/34996457 http://dx.doi.org/10.1186/s12944-021-01610-w |
_version_ | 1784629690122633216 |
---|---|
author | Peng, Jia Liu, Ming-Ming Jin, Jing-Lu Cao, Ye-Xuan Guo, Yuan-Lin Wu, Na-Qiong Zhu, Cheng-Gang Dong, Qian Sun, Jing Xu, Rui-Xia Li, Jian-Jun |
author_facet | Peng, Jia Liu, Ming-Ming Jin, Jing-Lu Cao, Ye-Xuan Guo, Yuan-Lin Wu, Na-Qiong Zhu, Cheng-Gang Dong, Qian Sun, Jing Xu, Rui-Xia Li, Jian-Jun |
author_sort | Peng, Jia |
collection | PubMed |
description | BACKGROUND: The risk of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) can be easily evaluated by noninvasive scoring systems, of which the NAFLD fibrosis score (NFS) is the most commonly used. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a new predictor of cardiovascular events, has been reported to be associated with cardiovascular outcomes and NAFLD. However, the relationship of NFS with PCSK9 and their prognostic abilities in cardiovascular risks are unknown. METHODS: A total of 2008 hospitalized subjects who had chest pain without lipid-lowering therapy were consecutively included. Baseline clinical data were collected, and the NFS was calculated. The circulating PCSK9 concentration was determined by enzyme immunoassay. The major adverse cardiovascular event (MACE) occurrences were recorded in the follow-up period. Associations of PCSK9 concentration with NFS were examined. All of the participants were categorized into three groups according to NFS levels and were further stratified by PCSK9 tertiles to evaluate the MACEs. RESULTS: 158 (7.87%) MACEs were observed during a mean of 3.2 years of follow-up. NFS levels were independently related to higher PCSK9 levels according to multivariable linear regression analysis. Furthermore, elevated PCSK9 and NFS concentrations were respectively associated with increased MACE incidence in multivariable Cox regression models. When combining NFS status with PCSK9 tertiles as a stratifying factor, patients with intermediate-high NFS and high PCSK9 levels had higher risks of events than those with low NFS and low PCSK9 levels. CONCLUSIONS: This study revealed for the first time that NFS is positively related to PCSK9 and that the combination of NFS and PCSK9 greatly increased the risk of MACEs in patients with chest pain, providing a potential link between NFS and PCSK9 for predicting cardiovascular events. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12944-021-01610-w. |
format | Online Article Text |
id | pubmed-8742334 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-87423342022-01-10 NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study Peng, Jia Liu, Ming-Ming Jin, Jing-Lu Cao, Ye-Xuan Guo, Yuan-Lin Wu, Na-Qiong Zhu, Cheng-Gang Dong, Qian Sun, Jing Xu, Rui-Xia Li, Jian-Jun Lipids Health Dis Research BACKGROUND: The risk of liver fibrosis in non-alcoholic fatty liver disease (NAFLD) can be easily evaluated by noninvasive scoring systems, of which the NAFLD fibrosis score (NFS) is the most commonly used. Proprotein convertase subtilisin/kexin type 9 (PCSK9), a new predictor of cardiovascular events, has been reported to be associated with cardiovascular outcomes and NAFLD. However, the relationship of NFS with PCSK9 and their prognostic abilities in cardiovascular risks are unknown. METHODS: A total of 2008 hospitalized subjects who had chest pain without lipid-lowering therapy were consecutively included. Baseline clinical data were collected, and the NFS was calculated. The circulating PCSK9 concentration was determined by enzyme immunoassay. The major adverse cardiovascular event (MACE) occurrences were recorded in the follow-up period. Associations of PCSK9 concentration with NFS were examined. All of the participants were categorized into three groups according to NFS levels and were further stratified by PCSK9 tertiles to evaluate the MACEs. RESULTS: 158 (7.87%) MACEs were observed during a mean of 3.2 years of follow-up. NFS levels were independently related to higher PCSK9 levels according to multivariable linear regression analysis. Furthermore, elevated PCSK9 and NFS concentrations were respectively associated with increased MACE incidence in multivariable Cox regression models. When combining NFS status with PCSK9 tertiles as a stratifying factor, patients with intermediate-high NFS and high PCSK9 levels had higher risks of events than those with low NFS and low PCSK9 levels. CONCLUSIONS: This study revealed for the first time that NFS is positively related to PCSK9 and that the combination of NFS and PCSK9 greatly increased the risk of MACEs in patients with chest pain, providing a potential link between NFS and PCSK9 for predicting cardiovascular events. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12944-021-01610-w. BioMed Central 2022-01-07 /pmc/articles/PMC8742334/ /pubmed/34996457 http://dx.doi.org/10.1186/s12944-021-01610-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Peng, Jia Liu, Ming-Ming Jin, Jing-Lu Cao, Ye-Xuan Guo, Yuan-Lin Wu, Na-Qiong Zhu, Cheng-Gang Dong, Qian Sun, Jing Xu, Rui-Xia Li, Jian-Jun NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study |
title | NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study |
title_full | NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study |
title_fullStr | NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study |
title_full_unstemmed | NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study |
title_short | NAFLD fibrosis score is correlated with PCSK9 and improves outcome prediction of PCSK9 in patients with chest pain: a cohort study |
title_sort | nafld fibrosis score is correlated with pcsk9 and improves outcome prediction of pcsk9 in patients with chest pain: a cohort study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742334/ https://www.ncbi.nlm.nih.gov/pubmed/34996457 http://dx.doi.org/10.1186/s12944-021-01610-w |
work_keys_str_mv | AT pengjia nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT liumingming nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT jinjinglu nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT caoyexuan nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT guoyuanlin nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT wunaqiong nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT zhuchenggang nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT dongqian nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT sunjing nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT xuruixia nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy AT lijianjun nafldfibrosisscoreiscorrelatedwithpcsk9andimprovesoutcomepredictionofpcsk9inpatientswithchestpainacohortstudy |